Mereo BioPharma
Nasdaq MREO · London, United Kingdom
Works in Genetic & rare · GI & liver · Infectious disease · Metabolic & endocrine · Oncology · Respiratory
Mereo BioPharma is a clinical trial sponsor based in London, United Kingdom, listed as Nasdaq MREO. It has no active clinical trials as lead sponsor; its trials since 2021 were across 6 therapeutic areas. Since 2021 it has completed 5 trials and stopped 0 early.
Trial track record · since 2021
Financials · Nasdaq MREO
Pipeline · 0 active trials
No active trials with this company as lead sponsor.
Questions about Mereo BioPharma
Mereo BioPharma has no active clinical trials as lead sponsor on ClinicalTrials.gov. Since 2021 it has completed 5 trials and stopped 0 early.
Mereo BioPharma is based in London, United Kingdom and is listed as Nasdaq MREO. The address is the one on its SEC filings, which name the establishment or the registrant, not always the group's head office.
From public sources only: ClinicalTrials.gov for trials, FDA's Data Dashboard, warning-letter listing and enforcement reports for the FDA record, and SEC filings for financials. Approve Suite is not affiliated with Mereo BioPharma; every record links to the source, and nothing here is advice.
See the rest of this profile
A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.
Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2025-03-17.
Approve Suite is not affiliated with Mereo BioPharma.
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.